Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Radiant Research
350
mi
from 43215
Greer, SC
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Radiant Research
350
mi
from 43215
Greer, SC
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Neurology and Pain Clinic, LLC
463
mi
from 43215
Orangeburg, SC
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Neurology and Pain Clinic, LLC
463
mi
from 43215
Orangeburg, SC
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
University Diabetes and Endocrine Consultants
361
mi
from 43215
Chattanooga, TN
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
University Diabetes and Endocrine Consultants
361
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from 43215
Jackson, TN
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from 43215
Jackson, TN
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
AM Diabetes & Endocrinology Center
mi
from 43215
Memphis, TN
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
AM Diabetes & Endocrinology Center
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
ClinRX Research LLC
898
mi
from 43215
Carrollton, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
ClinRX Research LLC
898
mi
from 43215
Carrollton, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Baylor University Medical Center
910
mi
from 43215
Dallas, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Baylor University Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
911
mi
from 43215
Dallas, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
The Medical Group of Texas
938
mi
from 43215
Fort Worth, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
The Medical Group of Texas
938
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
ClinRx Research, LLC
900
mi
from 43215
Richardson, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
ClinRx Research, LLC
900
mi
from 43215
Richardson, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Paragon Research Center
1137
mi
from 43215
San Antonio, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Paragon Research Center
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Cetero Research - San Antonio
1138
mi
from 43215
San Antonio, TX
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Cetero Research - San Antonio
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
L. Craig Larsen and Clark C. Larsen
mi
from 43215
Murray, UT
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
L. Craig Larsen and Clark C. Larsen
mi
from 43215
Murray, UT
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Aspen Clinical Research, LLC
1509
mi
from 43215
Orem, UT
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Aspen Clinical Research, LLC
1509
mi
from 43215
Orem, UT
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Daniel B. Vine, MD
mi
from 43215
Salt Lake City, UT
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Daniel B. Vine, MD
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Wasatch Clinical Research
1514
mi
from 43215
Salt Lake City, UT
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Wasatch Clinical Research
1514
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
Neurological Associates, Incorporated
mi
from 43215
Henrico, VA
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
Neurological Associates, Incorporated
mi
from 43215
Henrico, VA
Click here to add this to my saved trials
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated:  12/31/1969
University of Calgary
mi
from 43215
Calgary,
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status: Enrolling
Updated: 12/31/1969
University of Calgary
mi
from 43215
Calgary,
Click here to add this to my saved trials
Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
Status: Enrolling
Updated:  12/31/1969
Oakwood Dearborn Hospital
163
mi
from 43215
Dearborn, MI
Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
Status: Enrolling
Updated: 12/31/1969
Oakwood Dearborn Hospital
163
mi
from 43215
Dearborn, MI
Click here to add this to my saved trials
Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
Status: Enrolling
Updated:  12/31/1969
Oakwood Southshore Hospital
150
mi
from 43215
Trenton, MI
Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
Status: Enrolling
Updated: 12/31/1969
Oakwood Southshore Hospital
150
mi
from 43215
Trenton, MI
Click here to add this to my saved trials
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated:  12/31/1969
Kennedy Krieger Institute
345
mi
from 43215
Baltimore, MD
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated: 12/31/1969
Kennedy Krieger Institute
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated:  12/31/1969
Ohio State University
2
mi
from 43215
Columbus, OH
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated: 12/31/1969
Ohio State University
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Exome Sequencing in Autistic Spectrum Disorder
Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.
Status: Enrolling
Updated:  12/31/1969
Quietmind Foundation
408
mi
from 43215
Plymouth Meeting, PA
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.
Status: Enrolling
Updated: 12/31/1969
Quietmind Foundation
408
mi
from 43215
Plymouth Meeting, PA
Click here to add this to my saved trials
Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck
A Study of Late Effects After Proton Radiotherapy for Pediatric Tumors of the Brain, Head, and Neck
Status: Enrolling
Updated:  12/31/1969
University of Florida Proton Therapy Institute
668
mi
from 43215
Jacksonville, FL
Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck
A Study of Late Effects After Proton Radiotherapy for Pediatric Tumors of the Brain, Head, and Neck
Status: Enrolling
Updated: 12/31/1969
University of Florida Proton Therapy Institute
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1327
1651
mi
from 43215
Gilbert, AZ
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1327
1651
mi
from 43215
Gilbert, AZ
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 34
1662
mi
from 43215
Phoenix, AZ
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 34
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1326
1960
mi
from 43215
Fullerton, CA
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1326
1960
mi
from 43215
Fullerton, CA
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 04
1953
mi
from 43215
La Jolla, CA
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 04
1953
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1297
1153
mi
from 43215
Aurora, CO
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1297
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1344
1174
mi
from 43215
Boulder, CO
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1344
1174
mi
from 43215
Boulder, CO
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1315
1158
mi
from 43215
Centennial, CO
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1315
1158
mi
from 43215
Centennial, CO
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1345
996
mi
from 43215
Miami, FL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1345
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10
957
mi
from 43215
Naples, FL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10
957
mi
from 43215
Naples, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1347
963
mi
from 43215
Pompano Beach, FL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1347
963
mi
from 43215
Pompano Beach, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1298
872
mi
from 43215
Sarasota, FL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1298
872
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 61
864
mi
from 43215
Vero Beach, FL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 61
864
mi
from 43215
Vero Beach, FL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1303
291
mi
from 43215
Northbrook, IL
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1303
291
mi
from 43215
Northbrook, IL
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 17
154
mi
from 43215
Lexington, KY
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 17
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11
163
mi
from 43215
Detroit, MI
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1329
110
mi
from 43215
Akron, OH
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1329
110
mi
from 43215
Akron, OH
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1
mi
from 43215
Columbus, OH
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1313
63
mi
from 43215
Dayton, OH
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1313
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1318
109
mi
from 43215
Uniontown, OH
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1318
109
mi
from 43215
Uniontown, OH
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
849
mi
from 43215
Oklahoma City, OK
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1310
332
mi
from 43215
Nashville, TN
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1310
332
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1321
1128
mi
from 43215
Lubbock, TX
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1321
1128
mi
from 43215
Lubbock, TX
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1138
mi
from 43215
San Antonio, TX
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1343
1513
mi
from 43215
Salt Lake City, UT
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1343
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 09
344
mi
from 43215
Richmond, VA
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 09
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials